These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 22825555)
21. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902 [TBL] [Abstract][Full Text] [Related]
22. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Mulders PF; De Santis M; Powles T; Fizazi K Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563 [TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Lü C; Williams AK; Chalasani V; Martínez CH; Chin J Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858 [TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy: an emerging strategies against prostate castration resistant cancer]. Mansi L; Thiery-Vuillemin A; Kalbacher E; Nguyen T; Maurina T; Nallet J; Kim S; Borg C; Kleinclauss F; Pivot X; Adotevi O Bull Cancer; 2012 Jul; 99 Suppl 1():S57-65. PubMed ID: 22516539 [TBL] [Abstract][Full Text] [Related]
25. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Cheever MA; Higano CS Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425 [TBL] [Abstract][Full Text] [Related]
27. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. McKarney I Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg? Laccetti AL; Subudhi SK Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923 [TBL] [Abstract][Full Text] [Related]
29. NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer. Lovett R; George E; Adler A Lancet Oncol; 2015 Apr; 16(4):369-70. PubMed ID: 25732545 [No Abstract] [Full Text] [Related]
30. Sipuleucel-T (APC8015) for prostate cancer. So-Rosillo R; Small EJ Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451 [TBL] [Abstract][Full Text] [Related]
31. How does sipuleucel-T alter our clinical practice? George D BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691 [No Abstract] [Full Text] [Related]
32. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer. Becze E ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750 [No Abstract] [Full Text] [Related]
36. Immunotherapy: a new option for advanced prostate cancer. Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869 [No Abstract] [Full Text] [Related]
37. Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer. Kittai A; Meshikhes M; Aragon-Ching JB Cancer Biol Ther; 2014 Oct; 15(10):1299-300. PubMed ID: 25046606 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. Botrel TE; Clark O; Pompeo AC; Bretas FF; Sadi MV; Ferreira U; Reis RB Int Braz J Urol; 2012; 38(6):717-27. PubMed ID: 23302410 [TBL] [Abstract][Full Text] [Related]
39. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]